Live
On Monday, Glenmark Life Sciences shares had slipped below their issue price of Rs 720 per share on the Bombay Stock Exchange (BSE) in intra-day trade as the stock declined 5 per cent to Rs 713.85. On the other hand, the pharmaceutical company’s supply has dropped 11 per cent from its listing day high of Rs 799.95.
- Piramal Finance Q2 Profit Jumps 67% to Rs 545 Cr
- IRDAI plans lower commissions, minor hit for PSU Banks
- SML Mahindra Q2 Sales Rise 20.7% but Profit Falls 44%
- Hindustan Zinc Q2 Profit Jumps 142% to Record Rs 6,412 Cr
- Aeroflex Industries Gets Indian Patent for 3D Hose Design Tool
On August 6 2021, GLS had made a quiet debut on the bourses as the shares listed at Rs 751.10, a 4 per cent premium against the issue price on the BSE.
GLS, a developer and manufacturer of active pharmaceutical ingredients (APIs), is a wholly-owned subsidiary of Glenmark Pharmaceuticals. The company on Friday informed the stock exchanges that the board of directors of the company is scheduled to meet on Friday, August 13, 2021, to consider and approve the company’s unaudited financial results for the first quarter ended June 30, 2021 (Q1FY22).
Stock Covered in the news
